VJOncology Podcast

In this week’s podcast, we bring you updates from the ESMO 2024 Congress in Barcelona, Spain, featuring expert discussions on cutting-edge oncology research. We are joined by Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK; Minke Lukas, MD, Netherlands Cancer Institute, Amsterdam, Netherlands; Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL; Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden Hospital, London, UK; Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Italy; and Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Germany.

We’ll hear about final overall survival results from the Phase III KEYNOTE-522 trial (NCT03036488) of pembrolizumab in triple-negative breast cancer, updates from the Phase III NADINA trial (NCT04949113) of ipilimumab and nivolumab in melanoma, and findings from the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in urothelial carcinoma, as well as the Phase III NIAGARA trial (NCT03732677) of neoadjuvant immunotherapy in muscle-invasive bladder cancer. Other highlights include data from the Phase III MARIPOSA-2 trial (NCT04487080) of amivantamab in EGFR-mutant lung cancer, the Phase III KEYNOTE-A18 (NCT04221945) study in cervical cancer, and the Phase III POD1UM-303 trial (NCT04472429) of retifanlimab in squamous cell anal carcinoma.

For more exclusive content on ESMO 2024, visit VJOncology.com.

The post Highlights from ESMO 2024 appeared first on VJOncology.

In this podcast, we bring you the latest insights into managing brain metastases, with expert commentary from Minesh Mehta, MD, Miami Cancer Institute, Miami, FL; Sunandana Chandra, MD, MS, Northwestern University, Chicago, IL; Gaia Griguolo, MD, University of Padova, Padova, Italy; Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel; and Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China,.

We will cover key findings from the Phase III METIS trial (NCT02831959), which explored Tumor Treating Fields (TTFields) therapy in patients with non-small cell lung cancer and brain metastases. Other topics include the complexities of managing symptomatic brain metastases in melanoma, new advances in breast cancer treatment with anti-HER2 agents, and the role of radiotherapy in preserving cognitive function. Finally, we’ll discuss data from the DESTINY-Breast01, -02, and -03 trials (NCT03248492, NCT03523585, NCT03529110) on the CNS efficacy of trastuzumab deruxtecan (T-DXd).

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit VJOncology.com.

The post Latest updates in managing brain metastases appeared first on VJOncology.

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat genitourinary cancer. This week we will be joined by Camillo Porta, MD, University of Bari Aldo Moro, Bari, Italy, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA,  Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Maria Bourlon, MD, MS, El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

We will cover findings from key trials, including CHECKMATE 901 on nivolumab with gemcitabine and cisplatin for metastatic urothelial carcinoma; JAVELIN Renal 101 comparing avelumab plus axitinib with sunitinib for advanced renal cell carcinoma; a JAVELIN Bladder 100 post hoc analysis on avelumab for first-line maintenance in advanced urothelial carcinoma; TROPiCS-04 on sacituzumab govitecan in advanced urothelial carcinoma; and CheckMate 67T comparing subcutaneous and intravenous nivolumab for advanced renal cell carcinoma

For other GU cancer news, be sure to visit our dedicated GU Cancer Channel.

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

The post Updates in immunotherapy for GU cancer appeared first on VJOncology.

In this week’s podcast, we will be covering recent updates and integrating precision medicine for the treatment of colorectal cancer. We’ll be covering a wide range of topics including biomarker-driven treatments, challenges in using minimal residual disease in the clinic and more.

Listen to expert insights from Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX, Giulia Martini, University of Campania Luigi Vanvitelli, Naples, Italy, Paolo Manca, Memorial Sloan Kettering Cancer Center, New York, NY, and Eric Christensen, John Hopkins Medicine, Baltimore, MD, as they discuss hurdles and opportunities in precision medicine for colorectal cancer.

The post Advancements in precision medicine for colorectal cancer appeared first on VJOncology.

In this podcast, we join leading experts Randy Hecht from UCLA, Diane Simeone from University of California San Diego, and Ben Schechter from Dana-Farber Cancer Institute as they delve into groundbreaking advancements in GI cancer therapies, as presented at the latest iwCAR-T workshop in Miami, Florida.

Explore the latest updates and insights on translational research in pancreatic cancer, including innovative biopsy techniques and the evolving role of immuno-oncology in treating solid tumors. Discover the potential of new cell therapies like TAC T-cells and the promising Claudin 18.2-targeted therapies, highlighting their efficacy and safety profiles. These discussions underscore the need for continued research in precision oncology and the adaptation of hematologic malignancy successes to solid tumors.

The post iwCAR-T sessions: clinical advances in GI Cancers appeared first on VJOncology.

In this week’s podcast, we join experts Allison Betof Warner from Stanford Medicine, Amod Sarnaik from Moffitt Cancer Center, and Elizabeth Loggers from Fred Hutchinson Cancer Center on transformative innovations in cell therapies for melanoma and sarcomas, as presented at the most recent iwCAR-T workshop in Miami, Florida.

Discover the latest updates and perspectives on advanced TIL therapies, including their promising progression-free survival results and new protocols for melanoma-induced brain metastases, along with updates on TCR-based therapies for synovial sarcoma. These developments underscore the need for continued research in adjuvant treatment settings and tumor immunology.

The post iwCAR-T sessions: cell therapies for melanoma and sarcomas appeared first on VJOncology.

In this week’s episode, we join Jennifer Specht from Fred Hutchinson Cancer Center, Saurabh Garg from Moffitt Cancer Center, and Rizwan Romee from Dana-Farber Cancer Institute on pioneering advancements in CAR-T cell therapies for breast and gynecological cancers, as discussed at the recent 6th annual iwCAR-T workshop in Miami, Florida.

Tune in to learn about the fascinating evolution of ROR1-targeting CAR-T cells for triple negative breast cancer, NK-cell targeting CAR-T therapeutics in ovarian cancer, and combinatorial therapy using dendritic cells against HER2-positive breast cancer.  As their development progresses, several challenges and advantages come to light.

The post iwCAR-T sessions: Advances in breast and gynecological cancers appeared first on VJOncology.

Welcome to another episode of VJOncology! In this episode, we dive into cutting-edge CAR-T cell therapies for the management of lung cancers, discussed at the sixth International Workshop on CAR-T in Miami, Florida.

Join Julian Molina from the Mayo Clinic, Ben Creelan from Moffitt Cancer Center, and Adam Schoenfeld from Memorial Sloan Kettering Cancer Center as they explore innovative CAR-T strategies and their applications in thoracic oncology. They address the challenges of integrating cell therapies in clinical practice, the potential for tumor cell banking, and the implications of tumor microenvironment modulation.

Discover insights into the latest developments in claudin-targeting CAR-T cells for non-small cell lung cancer and the exciting prospects of DLL3-targeting therapies for neuroendocrine tumors. This episode provides a comprehensive overview of the future landscape of cell therapy in lung cancer treatment.

Don’t miss this enlightening discussion! Subscribe and leave a review on your favorite podcast app. Follow us on Twitter at VJOncology and visit vjoncology.com for more content from the International Workshop on CAR-T.

The post iwCAR-T sessions: clinical advances in lung cancer appeared first on VJOncology.

In this week’s podcast, we will discuss the most recent developments in colorectal cancer from the 2024 ASCO and ESMO Gastrointestinal (GI) Annual Meetings held in Chicago, IL and Munich, Germany respectively. Join us as five renowned experts discuss highly anticipated findings from clinical trials across different colorectal cancer subtypes.

Heinz-Josef Lenz from the University of Southern California first comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer and Sara Lonardi from the Veneto Institute of Oncology in Padua, Italy, discusses the health-related quality of life outcomes from the trial. John Strickler from Duke University then provides 32 month follow-up data from the MOUNTAINEER trial of tucatinib and trastuzumab in HER2+ colorectal cancer. Additionally, listen to insightful perspectives from Major Lee, The University of Pennsylvania, and David Tougeron, Poitiers University Hospital, on practice changing trials in colorectal cancer.

The post Highlights in colorectal cancer at ASCO and ESMO GI 2024 appeared first on VJOncology.

Welcome to another episode of VJ Oncology Podcasts! Today, we spotlight key advances in skin cancer research shared at ASCO 2024. Join us as six leading experts reveal groundbreaking findings from recent clinical trials.

First, Georgina Long from the University of Sydney discusses the NADINA trial, a landmark Phase III study on neoadjuvant immunotherapy for melanoma. Next, Omid Hamid from The Angeles Clinic presents early results from a Phase I trial of IMC-F106C in metastatic cutaneous melanoma. Hear insights from Meredith McKean, Sapna Patel, Joseph J. Sacco, and Rodabe Amaria on innovative therapies and trial results shaping the future of skin cancer treatment. Tune in for these and more exciting updates!

The post Skin Cancer Highlights at ASCO 2024 appeared first on VJOncology.